To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Athira Pharma snags $85m Series B
Seattle-based Athira Pharma Inc, a developer of regenerative therapies focused on restoring brain function, has closed $85 million in Series B financing.
